Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Electromed posts record 2026 results driven by homecare growth and leverage

Aug 25, 2026, 4:07 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The company posted durable top-line growth, expanding margins, a debt-free balance sheet, and a meaningful buyback, all of which tend to support upside in the near-to-intermediate term and could lead to multiple expansion if expectations for long-term bronchiectasis market uptake persist.

AI summary

What happened, with direct paths to the underlying reporting

Electromed reported FY2026 revenue of $73.8M, up 15.3%, and operating income of $13.9M (18.8% margin), with Q4 revenue of $19.4M (+11.6%). Direct homecare accelerated 16.3% to $66.6M, supported by a larger sales force and higher per-device revenue, while net income reached $11.3M. The company ended with a cash-rich balance sheet ($20.5M) and no debt, funding a $3.9M stock repurchase and reinforcing long-term growth optionality in the bronchiectasis market via SmartVest.

Q4 FY2026 revenue rose 11.6% to $19.4M; gross margin 78.7%.
FY2026 revenue up 15.3% to $73.8M; operating income $13.9M; margin 18.8%.
Direct homecare revenue up 16.3% to $66.6M; avg reps 58; per-rep $1,145,000.
Net income FY2026 $11.3M; EPS $1.30; cash from ops $9.7M; no debt.
Electromed bought back $3.9M of stock; cash balance $20.5M; bronchiectasis market focus.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.